<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">282</journal-id><journal-id journal-id-type="pmc-domain">brjpharm</journal-id><journal-id journal-id-type="publisher-id">BPH</journal-id><journal-title-group><journal-title>British Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7348097</article-id><article-id pub-id-type="pmcid-ver">PMC7348097.1</article-id><article-id pub-id-type="pmcaid">7348097</article-id><article-id pub-id-type="pmcaiid">7348097</article-id><article-id pub-id-type="pmid">32335903</article-id><article-id pub-id-type="doi">10.1111/bph.15079</article-id><article-id pub-id-type="publisher-id">BPH15079</article-id><article-id pub-id-type="other">2019-BJP-0038-RP.R3</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Papers</subject></subj-group></article-categories><title-group><article-title>Semi&#8208;mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities</article-title><alt-title alt-title-type="left-running-head">Venkatasubramanian et al.</alt-title></title-group><contrib-group><contrib id="bph15079-cr-0001" contrib-type="author"><name name-style="western"><surname>Venkatasubramanian</surname><given-names initials="R">Raja</given-names></name><xref ref-type="aff" rid="bph15079-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bph15079-cr-0002" contrib-type="author"><name name-style="western"><surname>Collins</surname><given-names initials="TA">Teresa A.</given-names></name><xref ref-type="aff" rid="bph15079-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bph15079-cr-0003" contrib-type="author"><name name-style="western"><surname>Lesko</surname><given-names initials="LJ">Lawrence J.</given-names></name><xref ref-type="aff" rid="bph15079-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bph15079-cr-0004" contrib-type="author"><name name-style="western"><surname>Mettetal</surname><given-names initials="JT">Jerome T.</given-names></name><xref ref-type="aff" rid="bph15079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bph15079-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Trame</surname><given-names initials="MN">Mirjam N.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1030-4986</contrib-id><xref ref-type="aff" rid="bph15079-aff-0001">
<sup>1</sup>
</xref><address><email>mirjam.trame@gmail.com</email></address></contrib></contrib-group><aff id="bph15079-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy</named-content>
<institution>University of Florida</institution>
<city>Orlando</city>
<named-content content-type="country-part">Florida</named-content>
<country country="US">USA</country>
</aff><aff id="bph15079-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Clinical Pharmacology and Safety Sciences</named-content>
<institution>R&amp;D, AstraZeneca</institution>
<city>Cambridge</city>
<country country="GB">UK</country>
</aff><aff id="bph15079-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Early TDE Discovery</named-content>
<institution>R&amp;D, AstraZeneca</institution>
<city>Waltham</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mirjam N. Trame, Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA.<break/>
Email: <email>mirjam.trame@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2020</year></pub-date><volume>177</volume><issue>15</issue><issue-id pub-id-type="pmc-issue-id">361152</issue-id><issue-id pub-id-type="doi">10.1111/bph.v177.15</issue-id><fpage>3568</fpage><lpage>3590</lpage><history><date date-type="received"><day>28</day><month>1</month><year>2019</year></date><date date-type="rev-recd"><day>22</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-08-01 00:16:35.090"><day>01</day><month>08</month><year>2021</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2020 The British Pharmacological Society</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BPH-177-3568.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BPH-177-3568.pdf"/><abstract><sec id="bph15079-sec-0001"><title>Background and Purpose</title><p>Cardiovascular safety is one of the most frequent causes of safety&#8208;related attrition both preclinically and clinically. Preclinical cardiovascular safety is routinely assessed using dog telemetry monitoring key cardiovascular functions. The present research was to develop a semi&#8208;mechanistic modelling platform to simultaneously assess changes in contractility (dPdt<sub>max</sub>), heart rate (HR) and mean arterial pressure (MAP) in preclinical studies.</p></sec><sec id="bph15079-sec-0002"><title>Experimental Approach</title><p>Data from dPdt<sub>max</sub>, HR, preload (left ventricular end&#8208;diastolic pressure [LVEDP]) and MAP were available from dog telemetry studies after dosing with atenolol (<italic toggle="yes">n</italic> = 27), salbutamol (<italic toggle="yes">n</italic> = 5), L&#8211;N<sup>G</sup>&#8211;nitroarginine methyl ester (L&#8211;NAME; <italic toggle="yes">n</italic> = 4), milrinone (<italic toggle="yes">n</italic> = 4), verapamil (<italic toggle="yes">n</italic> = 12), dofetilide (<italic toggle="yes">n</italic> = 8), flecainide (<italic toggle="yes">n</italic> = 4) and AZ001 (<italic toggle="yes">n</italic> = 14). Literature model for rat CV function was used for the structural population pharmacodynamic model development. LVEDP was evaluated as covariate to account for the effect of preload on dPdt<sub>max</sub>.</p></sec><sec id="bph15079-sec-0003"><title>Key Results</title><p>The model was able to describe drug&#8208;induced changes in dPdt<sub>max</sub>, HR and MAP for all drugs included in the developed framework adequately, by incorporating appropriate drug effects on dPdt<sub>max</sub>, HR and/or total peripheral resistance. Consistent with the Starling's law, incorporation of LVEDP as a covariate on dPdt<sub>max</sub> to correct for the preload effect was found to be statistically significant.</p></sec><sec id="bph15079-sec-0004"><title>Conclusions and Implications</title><p>The contractility and haemodynamics semi&#8208;mechanistic modelling platform accounts for diurnal variation, drug&#8208;induced changes and inter&#8208;animal variation. It can be used to hypothesize and evaluate pharmacological effects and provide a holistic cardiovascular safety profile for new drugs.</p></sec></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>AstraZeneca </institution><institution-id institution-id-type="open-funder-registry">10.13039/100004325</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="23"/><word-count count="11375"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.5 mode:remove_FC converted:10.07.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bph15079-cit-9001"><string-name name-style="western"><surname>Venkatasubramanian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Lesko</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Mettetal</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Trame</surname><given-names>MN</given-names></string-name>. <article-title>Semi&#8208;mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities</article-title>. <source xml:lang="en">Br J Pharmacol</source>. <year>2020</year>;<volume>177</volume>:<fpage>3568</fpage>&#8211;<lpage>3590</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15079</pub-id><pub-id pub-id-type="pmcid">PMC7348097</pub-id><pub-id pub-id-type="pmid">32335903</pub-id></mixed-citation>
</p></notes></front></article></pmc-articleset>